BETHESDA, Md., Aug. 27, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into an agreement to acquire Advent...
BETHESDA, Md., Aug. 27, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into an agreement to acquire Advent...
BETHESDA, Md., Aug. 18, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced with deep sadness the passing of its Senior Vice President and...
BETHESDA, Md., Aug. 18, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced with deep sadness the passing of its Senior Vice President and...
Northwest Biotherapeutics (OTC:NWBO) has outperformed the market over the past 5 years by 42.99% on an annualized basis producing an average annual return of 54.57%. Currently, Northwest Biotherapeutics has a market capitalization of $1.42 billion.
